Ob-Gyn UW-Madison

Dr. Lisa Barroilhet

Claim this profile

University of Wisconsin Carbone Cancer Center

Studies Ovarian Cancer
Studies Cervical Adenocarcinoma
15 reported clinical trials
28 drugs studied

Area of expertise

1Ovarian Cancer
Lisa Barroilhet has run 9 trials for Ovarian Cancer. Some of their research focus areas include:
Stage III
Stage IV
BRCA1 positive
2Cervical Adenocarcinoma
Lisa Barroilhet has run 6 trials for Cervical Adenocarcinoma. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
University Of Wisconsin - Carbone Cancer Center
Image of trial facility.
University Of Wisconsin Carbone Cancer Center - University Hospital

Clinical Trials Lisa Barroilhet is currently running

Image of trial facility.

RG1-VLP Vaccine

for HPV-Related Cancers

This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women. RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines. HPV is a common sexually-transmitted infection that can cause certain genital and oral cancers. RG1-VLP contains a protein of HPV type 16 (HPV16) with a slightly different structure than the licensed Gardasil-9 vaccine. Gardasil-9 is approved by the Federal Drug Administration to help protect against diseases caused by some types of HPV. Gardasil-9 also contains 9 different HPV proteins. Both vaccines contain alum to stimulate the immune system. The usual approach for the prevention of HPV-related cancers for patients who are at increased risk is to consider the currently approved HPV vaccine like Gardasil-9, as well as to be followed closely by their doctor to watch for the development of cancer via routine pap smears. This trial may allow researchers to find out whether the RG1-VLP vaccine can safely trigger an immune response against HPV in healthy women and if it is better or worse than the usual approach for the prevention of HPV-related cancers.
Recruiting0 awards Phase 1
Image of trial facility.

ZN-c3

for Serous Carcinoma

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Recruiting1 award Phase 21 criteria

More about Lisa Barroilhet

Clinical Trial Related6 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Lisa Barroilhet has experience with
  • Paclitaxel
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Laparotomy
  • Chemotherapy
  • Minimally Invasive Surgery
  • RG1-VLP Vaccine
Breakdown of trials Lisa Barroilhet has run
Ovarian Cancer
Cervical Adenocarcinoma
Ovarian Carcinoma
Serous Cystadenocarcinoma
Clear Cell Adenocarcinoma

Other Doctors you might be interested in

Ellen Hartenbach, MDUniversity of Wisconsin
Jennifer Wright, MDUniversity of Wisconsin
David F Jarrard, MDUniversity of Wisconsin Carbone Cancer Center

Frequently asked questions

Do I need insurance to participate in a trial?
What does Lisa Barroilhet specialize in?
Is Lisa Barroilhet currently recruiting for clinical trials?
Are there any treatments that Lisa Barroilhet has studied deeply?
What is the best way to schedule an appointment with Lisa Barroilhet?
What is the office address of Lisa Barroilhet?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security